BioNTech (NASDAQ:BNTX) Hits New 52-Week Low – Should You Sell?

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $79.52 and last traded at $81.4570, with a volume of 4313149 shares trading hands. The stock had previously closed at $102.16.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target on the stock. in a report on Monday, February 2nd. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the company from $115.00 to $142.00 in a research note on Friday, January 16th. HC Wainwright restated a “buy” rating and issued a $140.00 price objective on shares of BioNTech in a report on Thursday, December 11th. Finally, UBS Group upgraded shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $140.10.

BioNTech Price Performance

The stock has a market capitalization of $18.15 billion, a price-to-earnings ratio of -30.92 and a beta of 1.51. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $106.95 and its 200 day simple moving average is $103.02.

Institutional Trading of BioNTech

A number of large investors have recently bought and sold shares of the stock. Rhenman & Partners Asset Management AB raised its position in shares of BioNTech by 0.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after acquiring an additional 120 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in BioNTech by 0.8% in the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after purchasing an additional 127 shares during the period. Larson Financial Group LLC lifted its holdings in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. Probity Advisors Inc. grew its position in shares of BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after purchasing an additional 135 shares during the period. Finally, Profund Advisors LLC increased its position in shares of BioNTech by 3.6% during the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after acquiring an additional 149 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.